

Study of YK012 in Primary Membranous Nephropathy

NCT06982729

Status	RECRUITING
Phase	Phase 1
Sponsor	Excyte Biopharma Ltd
Enrollment	72 participants

Key Eligibility Criteria

Inclusion (7)

- Aged 18 to 80 years (inclusive), regardless of gender.
- Kidney biopsy-confirmed diagnosis of primary (idiopathic) membranous nephropathy within the past 10 years.
- Elevated 24-hour urine protein, meeting the pre-defined criteria.
- Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m² as calculated by the CKD-EPI equation.
- If currently taking an angiotensin-converting enzyme inhibitor (ACEi), angiotensin II receptor blocker (ARB), or sodium-glucose cotransporter-2 (SGLT-2) inhibitor, the dose must have been stable for at least 4 weeks prior to enrollment or since initiation of therapy.

... and 2 more (see full listing online)

Exclusion (17)

- Diagnosis of secondary membranous nephropathy.
- Any prior receipt of protocol-specified pharmacological treatment for membranous nephropathy.
- History of malignancy within 5 years prior to enrollment.
- Poorly controlled hypertension at enrollment.
- Severe renal dysfunction with prior dialysis or kidney transplantation within 6 months prior to enrollment.

... and 12 more (see full listing online)

Locations (1 total)

Peking University First Hospital, Beijing, Beijing Municipality, China